SU5416 (Semaxanib): Selective VEGFR2 Inhibitor for Angiogenesis and Immune Modulation

Executive Summary: SU5416 (Semaxanib) is a highly selective inhibitor of VEGFR2 (Flk-1/KDR) tyrosine kinase, blocking VEGF-stimulated endothelial cell proliferation and angiogenesis with low nanomolar IC₅₀ values in vitro (APExBIO). In vivo, single-dose administration (20 mg/kg, i.p.) with hypoxic exposure induces pulmonary hypertension and robustly suppresses tumor vascularization in rodent models (Zhang et al., 2024). SU5416 also acts as an aryl hydrocarbon receptor (AHR) agonist, upregulating IDO activity and promoting regulatory T cell differentiation, highlighting potential utility in immune modulation (see review). The compound is insoluble in water or ethanol, but dissolves in DMSO to ≥11.9 mg/mL and remains stable at -20°C for months. Its dual mechanism and benchmarked dosing have made SU5416 a cornerstone in angiogenesis and immunology research workflows, with validated application protocols and safety profiles at tested doses (APExBIO).

Biological Rationale

Angiogenesis, the formation of new blood vessels, is a fundamental process in tumor growth and metastasis. Vascular endothelial growth factor (VEGF) signaling via VEGFR2 (Flk-1/KDR) is the principal pathway driving endothelial proliferation and vascularization in both physiological and pathological contexts. Inhibition of VEGFR2 signaling impairs tumor neovascularization, restricting nutrient supply and suppressing tumor expansion. SU5416 (Semaxanib) was developed as a selective small-molecule inhibitor of VEGFR2, enabling precise modulation of this axis in research models (Related article). Unlike broad-spectrum kinase inhibitors, SU5416 delivers high specificity for VEGFR2, minimizing confounding off-target effects in experimental workflows and allowing high-fidelity mechanistic studies. Its secondary action as an AHR agonist enables investigation into immune tolerance and autoimmunity by modulating tryptophan metabolism and T cell differentiation (see immune applications).

Mechanism of Action of SU5416 (Semaxanib) VEGFR2 Inhibitor

SU5416 is a small-molecule inhibitor that targets the ATP-binding domain of VEGFR2 (Flk-1/KDR), preventing VEGF-induced receptor autophosphorylation. This blockade suppresses downstream signaling cascades (e.g., MAPK, PI3K-Akt), resulting in inhibition of endothelial cell proliferation, migration, and tube formation. Typical in vitro IC₅₀ values for VEGF-driven mitogenesis in human umbilical vein endothelial cells (HUVECs) are 0.04 ± 0.02 μM under standard cell culture conditions (APExBIO). In vivo, SU5416 is administered via intraperitoneal injection (1–25 mg/kg daily) or as a single 20 mg/kg dose followed by hypoxic exposure for pulmonary hypertension modeling (Zhang et al., 2024). As an AHR agonist, SU5416 induces indoleamine 2,3-dioxygenase (IDO) expression, enhancing regulatory T cell (Treg) differentiation and modulating immune responses (see review).

Evidence & Benchmarks

• In vitro, SU5416 inhibits VEGF-stimulated mitogenesis in HUVECs with an IC₅₀ of 0.04 ± 0.02 μM under standard culture conditions (APExBIO).
• Single-dose (20 mg/kg, i.p.) SU5416 combined with 3 weeks of hypoxia reliably induces severe pulmonary hypertension in both Sprague–Dawley and Fischer rat models, confirming its biological activity in vivo (Zhang et al., 2024).
• Daily dosing (1–25 mg/kg, i.p.) suppresses tumor vascularization and significantly inhibits tumor growth in mouse xenograft models, with no mortality observed at upper dosing limits (APExBIO).
• In severe PH rat models, exercise capacity is reduced due to cardiopulmonary impairments rather than intrinsic skeletal muscle dysfunction, validating SU5416’s role in disease modeling without confounding systemic toxicity (Zhang et al., 2024).
• SU5416 increases IDO expression and promotes regulatory T cell differentiation in vitro and in vivo, supporting its dual application in immune modulation (see review).

This article extends previous coverage (review of atomic evidence) by integrating recent findings on SU5416’s immune effects and validated PH protocols.

Applications, Limits & Misconceptions

SU5416 is extensively used in cancer research as a highly selective VEGFR2 tyrosine kinase inhibitor for studying VEGF-induced angiogenesis inhibition and tumor vascularization suppression. It is also a standard tool in pulmonary hypertension models, where it reliably induces PH in rodents for mechanistic, pharmacological, and therapeutic investigations (Zhang et al., 2024). The immune-modulatory properties via AHR agonism and IDO induction enable research into autoimmune disease, tolerance, and transplantation immunology.

However, SU5416’s selectivity profile does not extend to all VEGF family receptors or unrelated kinases. It does not reverse established angiogenesis or PH but rather prevents or models their development. Its solubility constraints require careful handling, as the compound is insoluble in water or ethanol and must be prepared in DMSO at ≥11.9 mg/mL. Dosing above validated ranges or in non-rodent models requires new safety and efficacy assessments. Interference from other tyrosine kinase inhibitors or AHR ligands may confound mechanistic studies.

Common Pitfalls or Misconceptions

• SU5416 does not inhibit all VEGF receptor subtypes; its action is selective for VEGFR2 (Flk-1/KDR).
• It is not effective for reversing established angiogenesis or pulmonary hypertension; it is used for inhibition or induction, respectively (Zhang et al., 2024).
• SU5416 is insoluble in water and ethanol; improper solvent use can result in precipitation and experimental failure (APExBIO).
• High doses have not been validated in species beyond rodents; extrapolation to other models requires new toxicology data.
• Co-administration with other tyrosine kinase inhibitors or AHR agonists may result in non-additive, unpredictable effects.

Workflow Integration & Parameters

For in vitro studies, prepare SU5416 stock solution at ≥11.9 mg/mL in DMSO, warming to 37°C or sonicating as needed to enhance dissolution. Store aliquots at -20°C for up to several months (APExBIO). Typical effective concentrations in cell culture range from 0.01–100 μM depending on model and endpoint. For in vivo protocols, administer via intraperitoneal injection at 1–25 mg/kg daily for tumor models, or as a single 20 mg/kg dose for PH induction, followed by hypoxic exposure in rats (Zhang et al., 2024).

Quality control, dosing calibration, and negative controls (vehicle/DMSO) are essential for reproducibility. APExBIO supplies SU5416 (A3847) with validated benchmarking and standardized handling protocols for optimal integration into angiogenesis and immune modulation studies (product details).

This article updates details from earlier reviews (previous overview) by including new evidence on immune modulation and PH model specificity.

Conclusion & Outlook

SU5416 (Semaxanib) remains a robust, validated tool for targeted inhibition of VEGF-induced angiogenesis and tumor vascularization. Its unique dual action as a VEGFR2 tyrosine kinase inhibitor and AHR agonist enables advanced mechanistic, translational, and immunological studies. Ongoing research continues to refine its workflow integration and extend its utility in emerging disease models. For full product details and protocols, refer to the official SU5416 (Semaxanib) VEGFR2 inhibitor product page from APExBIO.